Study participants
cardiovascular and cerebrovascular diseases
CHRONIC DISEASES, INFLUENZA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MAY, MUMPS, HYPERTENSION, RABIES
In total, 211 volunteers aged ≥18 years who had received three doses of inactivated vaccine (CoronaVac or Covilo) ≥6 months earlier were recruited and screened for eligibility in May 2022. A total of 201 participants were sequentially enrolled and randomly assigned to two groups. One participant withdrew voluntarily after randomization. In total, 200 participants received a fourth dose of Convidecia (treatment group, heterologous booster dose, n = 100) or CoronaVac/Covilo (control group, homologous booster dose, n = 100). Finally, 95 (treatment group) and 96 (control group) participants completed both the follow-up at 6 months after vaccination and the telephone follow-up in March 2023, after the pandemic (Trial profile. A total of 211 volunteers were recruited and screened for eligibility. Overall, 201 participants were enrolled and randomly assigned, 200 participants received the booster dose vaccination, and one participant withdrew voluntarily after randomization. Participants in each group (n = 96 and n = 95) completed both the planned visits at 6 months after vaccination and the telephone follow-up in March 2023.Among the 191 participants who ultimately completed the follow-up, 87 (45.55%) were female and 56 (29.32%) had underlying chronic diseases. The mean patient age was 50.52 (standard deviation, 15.37) years. The mean time interval since the last booter dose of inactivated vaccine was 6.13 (standard deviation, 0.04) months. The baseline characteristics of the two vaccine groups were comparable (Comparison of baseline characteristics between the two vaccine groups.Influenza vaccination history within 1 year before the second booster dose of Ad5-nCoV or inactivated SARS-CoV-2 vaccine was collected; mumps and rabies vaccination history were collect without time limitation. Data are number of participants (%), mean (SD), or median (IQR). Underlying chronic diseases included cardiovascular and cerebrovascular diseases, hypertension, and chronic obstructive pulmonary disease. The comparison was analyzed using the Chi-squared test unless marked as 